Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.

NCT06762431 is registered in ClinicalTrials.gov with Vitebsk Regional Clinical Cancer Centre as lead sponsor.

NCT NCT06762431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06762431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
Lead sponsor
Vitebsk Regional Clinical Cancer Centre
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 14, 2024
Completion date
August 31, 2026
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukaemia (cll), small lymphocytic lymphoma (sll)